Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

RecruitingOBSERVATIONAL

Enrollment

800

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

December 24, 2025

Study Completion Date

December 24, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Third-generation EGFR-TKI

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

DRUG

EGFR-TKI

All EGFR-TKI

Trial Locations (1)

RECRUITING

Yongchang Zhang, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER